Aktiesnakken — Juni 2012
-
men det er over 1 mia stort det markedet
-
i uSDollar
-
det er nok 3-4 mia ihvertfald
-
spansk syge
-
genmab må godt går imod strømmen
-
well så er vi 2
-
trailing stop lyder ret proff
-
det er godt
-
Novo Nordisk to initiate phase 3 development of semaglutide, a once-weekly GLP-1 analogue (21 June 2012)
Read the full announcement in PDF format
Novo Nordisk today announced the decision to initiate the global phase 3 development programme for semaglutide, a once-weekly human GLP-1 (Glucagon-Like Peptide-1) analogue.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind